Copyright 1996 Legalsoft P10A/REV01

L OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c)) Martin Frederick Pera Examiner Serial No. Filing Date Group A 09/885,679 June 20, 2001 Unassigned Title: METHODS OF CULTURING EMBRYONIC STEM CELLS AND CONTROLLED DIFFERENTIATION **Payment of Fee** (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) A check in the amount of is attached. The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed. Charge the amount of \boxtimes Credit any overpayment. Charge any additional fee required. X Certificate of Mailing by First Class Mail Certificate of Transmission by Facsimile* dertify that this document and fee is being deposited certify that this document and authorization to charge an/01/01 with the U.S. Postal Service as deposit account is being facsimile transmitted to the United first class mail under 37 C.F.R. 1.8 and is addressed to the States Patent and Trademark Office (Fax. No. Assistant Commissioner for Patents, Washington, D.Ø 20231 (Date) Signature of Person Mailing Corr ignature Mishelle Mustafa Typed or Printed Name of Person Mailing Correspondence Typed or Printed Name of Person Signing Certificate *This certificate may only be used if paying by deposit account. Dated: November 1, 2001 Frank S. DiGiglio Registration No. 31,346 Scully, Scott, Murphy & Presser 400 Garden City Plaza Garden City, NY 11530 (516) 742-4343

P10A/REV01

cc:

AL OF INFORMATION DISCLOSURE STATEMENT Docket I (Under 37 CFR 1.97(b) or 1.97(c)) Of: Martin Frederick Pera Examiner Group Serial No. Filing Date 09/885,679 June 20, 2001 Unassigned Title: METHODS OF CULTURING EMBRYONIC STEM CELLS AND CONTROLLED DIFFERENTIATION Address to: Assistant Commissioner for Patents Washington, D.C. 20231 37 CFR 1.97(b) The Information Disclosure Statement submitted herewith is being filed within three months of the filing 1. 🛛 of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last. 37 CFR 1.97(c) The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either: 1. a Final Action under 37 CFR 1.113, or a Notice of Allowance under 37 CFR 1.311, 2. whichever occurs first. Also submitted herewith is: a certification as specified in 37 CFR 1.97(e); OR the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

Copyright 1996 Legalsoft P10A/REV01



<u>IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</u>

Examiner: Unassigned

Serial No.: 09/885,679

Art Unit: 1636

Filed: June 20, 2001

Docket: 14727

For: METHODS OF CULTURING EMBRYONIC

Dated: November 1, 2001

STEM CELLS AND CONTROLLED

DIFFERENTIATION

Assistant Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

- 1. United States Patent No. 6,087,168, issued July 11, 2000;
- 2. Lim, D. et al., "Noggin Antagonizes BMP Signaling to Create a Niche for Adult Neurogenesis", Neuron 28: 713-726 (2000);
- 3. Finley, M. et al., "BMP-4 Inhibits Neural Differentiation of Murine Embryonic Stem Cells", J. Neurobiol. 40: 271-287 (1999);
- 4. Canadian Patent Application No. 2174098, published April 20, 1995 (Abstract and Claims);

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231 on November 1, 2001.

Dated: November 1, 2001

Mishelle Mustafa

- 5. Ashton, Dr. Brian, "Noggin, A BMP Antagonist, Increases Proliferation, Differentiation And Mineralisation In Human Marrow Mesenchymal Stem Cells", <u>International Conference Bone Morphogenetiv Proteins 2000</u>, June 7-11, 2000 (Abstract);
- 6. Harland, Richard, "Noggin: Molecular Developmental Biology"

 <u>International Conference Bone Morphogenetic Proteins 2000</u>, June 7-11, 2000 (Abstract);
- 7. International Patent Application No. WO 98/30679, published July 16, 1998.

Applicant is submitting copies of the above-cited references. Reference no. 7 was cited in an International Search Report, dated November 8, 2000. The relevance of reference no. 7 has been described in the Search Report, a copy of which is enclosed.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required

Respectfully submitted,

Frank S. DiGiglio Registration No. 31,346

Scully, Scott, Murphy & Presser 400 Garden City Plaza Garden City, New York 11530 (516) 742-4343

FSD:PIB:lf